Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

The aim of this current study was to examine if daily vitamin D3 supplementation (cholecalciferol, 1000 IU/day) in pregnancy suppresses hepcidin concentration and/or affects iron body stores (ferritin) and inflammation (CRP and α1-acid glycoprotein (AGP)) compared to placebo.

Source: 1. Introduction. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Randomised controlled trial.

Randomised controlled trial

Assigns participants or groups to comparison interventions by chance.

Meta-analysis unclear · Double-blind reported · Human research reported

Reported blinded roles: participants.

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Using a subset of the UK multicenter Maternal Vitamin D Osteoporosis Study (MAVIDOS): a double-blinded, randomized, placebo-controlled trial (ISRCTN82927713; EudraCT2007-001716-23): we performed a secondary laboratory analysis.

Source: Abstract.

Using a subset of the UK multicenter Maternal Vitamin D Osteoporosis Study (MAVIDOS): a double-blinded, randomized, placebo-controlled trial (ISRCTN82927713; EudraCT2007-001716-23): we performed a secondary laboratory analysis.

Source: Abstract.

Women were screened for vitamin D status, and only those with 25OHD concentrations between 25 and 100 nmol/L and who were not currently taking dietary supplements with more than 400 IU of vitamin D/day were eligible.

Source: Methods.

Randomization was achieved by a computer-generated sequence in randomly permuted blocks of ten, and both the participants and research team were masked to treatment allocation.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

The Effect of Vitamin D Supplementation on Hepcidin, Iron Status, and Inflammation in Pregnant Women in the United Kingdom

Randomised controlled trial · Nutrients · 2019

Original publication title

The Effect of Vitamin D Supplementation on Hepcidin, Iron Status, and Inflammation in Pregnant Women in the United Kingdom

Vickie S. Braithwaite; Sarah R. Crozier; Stefania D’Angelo; Ann Prentice; Cyrus Cooper; Nicholas C. Harvey; Kerry S. Jones; the MAVIDOS Trial Group

© 2019 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Iron and vitamin D deficiencies are common during pregnancy. Our aim was to identify whether antenatal vitamin D3 supplementation affects iron status (via hepcidin suppression) and/or inflammation. Using a subset of the UK multicenter Maternal Vitamin D Osteoporosis Study (MAVIDOS): a double-blinded, randomized, placebo-controlled trial (ISRCTN82927713; EudraCT2007-001716-23): we performed a secondary laboratory analysis. Women with blood samples from early and late pregnancy (vitamin D3 (1000 IU/day from ~14 weeks gestation n = 93; placebo n = 102) who gave birth in the springtime (March: May) were selected as we anticipated seeing the greatest treatment group difference in change in 25-hydroxyvitamin D (25OHD) concentration.

Outcomes were hepcidin, ferritin, C-reactive protein, and α1-acid glycoprotein concentration in late pregnancy (25OHD concentration was measured previously). By late pregnancy, 25OHD concentration increased by 17 nmol/L in the vitamin D3 group and decreased by 11 nmol/L in the placebo group; hepcidin, ferritin, and inflammatory markers decreased but no treatment group differences were seen. In late pregnancy, positive relationships between 25OHD and hepcidin and 25OHD and ferritin in the placebo group were observed but not in the treatment group (group × 25OHD interaction, p < 0.02).

Vitamin D3 supplementation had no effect on hepcidin, ferritin, or inflammatory status suggesting no adjunctive value of vitamin D3 in reducing rates of antenatal iron deficiency.

Authors’ abstract

Iron and vitamin D deficiencies are common during pregnancy. Our aim was to identify whether antenatal vitamin D3 supplementation affects iron status (via hepcidin suppression) and/or inflammation. Using a subset of the UK multicenter Maternal Vitamin D Osteoporosis Study (MAVIDOS): a double-blinded, randomized, placebo-controlled trial (ISRCTN82927713; EudraCT2007-001716-23): we performed a secondary laboratory analysis. Women with blood samples from early and late pregnancy (vitamin D3 (1000 IU/day from ~14 weeks gestation n = 93; placebo n = 102) who gave birth in the springtime (March: May) were selected as we anticipated seeing the greatest treatment group difference in change in 25-hydroxyvitamin D (25OHD) concentration.

Outcomes were hepcidin, ferritin, C-reactive protein, and α1-acid glycoprotein concentration in late pregnancy (25OHD concentration was measured previously). By late pregnancy, 25OHD concentration increased by 17 nmol/L in the vitamin D3 group and decreased by 11 nmol/L in the placebo group; hepcidin, ferritin, and inflammatory markers decreased but no treatment group differences were seen. In late pregnancy, positive relationships between 25OHD and hepcidin and 25OHD and ferritin in the placebo group were observed but not in the treatment group (group × 25OHD interaction, p < 0.02).

Vitamin D3 supplementation had no effect on hepcidin, ferritin, or inflammatory status suggesting no adjunctive value of vitamin D3 in reducing rates of antenatal iron deficiency.

Publication and source details

Original title: The Effect of Vitamin D Supplementation on Hepcidin, Iron Status, and Inflammation in Pregnant Women in the United Kingdom

Vickie S. Braithwaite; Sarah R. Crozier; Stefania D’Angelo; Ann Prentice; Cyrus Cooper; Nicholas C. Harvey; Kerry S. Jones; the MAVIDOS Trial Group

Nutrients · 2019

* Correspondence: vb287@cam.ac.uk
†

Current address: MRC Nutrition and Bone Health Research Group, Clifford Allbutt Building, University of Cambridge, Cambridge CB2 0AH, UK.

‡

Membership of the MAVIDOS Trial Group is provided in the Acknowledgments.

© 2019 by the authors.2019https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T04:08:44.446200+00:00

DOI: 10.3390/nu11010190 · PMC6356300